Imagine CAR-T cells as specialized soldiers trained to kill cancer, but they often get tired or lose the scent of the enemy. This technology gives those soldiers a 'flare gun' that releases a signal to wake up the rest of the body's immune system. This creates a chain reaction where the body's own natural defenses join the fight to wipe out the tumor more effectively.
Current CAR-T therapies fail in 40-50% of patients due to antigen loss, cell exhaustion, and immunosuppression, particularly in solid tumors.
A fully-automated GMP manufacturing process for CAR20(NAP)-T cells and a platform to arm CAR-T cells with Neutrophil-Activating Protein (NAP).
If you are a biotech company dealing with the 40-50% of patients who relapse after standard CAR-T treatment — this project developed the iTANK platform that adds a dual mechanism of action to prevent cell exhaustion and overcome antigen loss.
If you are a research organization dealing with the difficulty of treating solid tumors due to immunosuppression — this project developed a GMP-ready manufacturing process for iTANK-armed cells that induces a pro-inflammatory microenvironment.
If you are a manufacturer dealing with inconsistent cell production — this project developed a fully-automated process for CAR20(NAP)-T manufacturing that meets strict release criteria.
Based on available project data, specific pricing is not mentioned, though the project received an EU contribution of EUR 2,499,999 for development.
Yes, the project has established a fully-automated manufacturing process and implemented it in a GMP lab to ensure the drug product meets release criteria.
Based on available project data, the technology is developed by Elicera Therapeutics AB, but specific licensing terms are not provided.
The project period runs from 2022-10-01 to 2025-09-30, with the goal of conducting First-in-Human clinical trials.
The iTANK technology is designed to be universally compatible and can be used to enhance the efficacy of other current or under-development CAR-T therapies.
The project is led by a single Swedish SME, Elicera Therapeutics AB, which holds 100% of the industry ratio. This lean structure indicates a highly focused commercial drive, with the company managing everything from GMP process establishment to clinical trial execution.
Contact Elicera Therapeutics AB in Sweden regarding iTANK licensing
Request a detailed technical briefing on iTANK GMP processes
